OncBioMune setting up for 2 Phase 2 trials in the U.S. for ProscaVax
ProscaVax – A Novel Prostate Cancer Vaccine
The Company has developed a therapeutic cancer vaccine for prostate cancer patients using similar techniques developed for breast cancer patients. It is tested and laboratory proven and could become the standard of care for prostate cancer treatment. The Company incorporates scientifically proven and clinically validated treatments for cancer. We utilize patented technology developed and or acquired by OncBioMune. The intellectual property consists of multiple technologies combined with laboratory and clinical procedures that provide new insight into the treatment of cancer. The Company’s proprietary technology provides the necessary tools for the successful treatment of patient’s with a therapeutic vaccine. It is marketable and would be very profitable upon FDA approval.
The Company has data from a phase 1/2 clinical trial of their therapeutic prostate cancer vaccine. Patients with prostate cancer confirmed by biopsy and with an elevated PSA received the vaccine. We enrolled 12 patients in this study. All patients received their initial course of six vaccinations containing prostate specific antigen and biological adjuvant. Serum PSA concentrations were determined before initiating vaccination and 3-4 weeks after the 6th vaccination. Two-thirds of the prostate cancer patients’ PSAs decreased after vaccination. During the trial the prostate cancer patients received no other concurrent therapy (surgery, hormone, radiation, radioactive seeds, chemotherapy), and have additionally received three further vaccinations alternated with low dose IL-2 for the 6 months following the initial vaccinations. The Company developed the protocol for the vaccination of prostate cancer patients using techniques developed for vaccination of breast cancer patients. We are currently in a Phase 1 clinical trial at UCSD Medical School under an IND from the FDA with funding from the US Navy Cancer Vaccine Program. If proven effective clinically, it could become the standard of care for prostate cancer.
Information on the current clinical trial of ProscaVax can be found on the clinictrials.gov at https://clinicaltrials.gov/ct2/show/NCT020586...amp;rank=1.
OncBiomune's ProscaVax phase 2 trial investigators Beth Israel Deaconess Medical Center of Harvard Medical School...
Glenn J. Bubley, MD, Director of Genitourinary Oncology
Dr. Glenn Bubley is a renowned expert in genitourinary (GU) medical oncology with a primary focus on prostate cancer. As director of the multidisciplinary genitourinary cancer program involving medical, surgical and radiation oncologists as well as pathologists and basic scientists, he heads numerous clinical/translational trials. He is Co-Principal Investigator for the prestigious Prostate SPORE (Specialized Programs of Research Excellence) at the Dana Farber/Harvard Cancer Center. The research is a pilot of the development of an anti-prostate cancer agent specifically targeted to prostate cancer cells. He oversees the Hershey Family Prostate Cancer Tissue Bank and Data base at BIDMC, which has more than 1,000 specimens from prostate cancer patients over the past 13 years and directs interventional research for GU oncology as well, overseeing approximately 13 open trials for patients with prostate or bladder cancer. Dr. Bubley has authored numerous scientific, research and translation papers and articles in his area of expertise, prostate cancer. He serves as at BIDMC and is Associate Professor of Medicine at Harvard Medical School.
Rupal Bhatt, MD, PhD, MMS
Dr. Rupal Bhatt is Assistant Professor of Medicine at Harvard Medical School, an attending physician in the GU Oncology Program and researcher Dr. Bhatt currently cares for patients with prostate, bladder and testis cancer and has participated in clinical trials in these fields. Dr. Bhatt focuses her research on Renal Cell Carcinoma and Prostate Cancer with a special interest in the Mechanisms of Resistance to Antiangiogenic Therapy. For this work, she was awarded Young Investigator Awards from AACR and ASCO and was also was awarded the ASCO Career Development Award. Currently Dr. Bhatt is in the second year of her five-year Mentored Clinical Scientist Development Award from the National Cancer Institute designed to train clinicians committed to a career in laboratory or field-based research or to translational research with a laboratory focus.
She completed her medical training and graduate training at Cornell University Medical College and The Rockefeller University, where she received her MD/PhD degrees. She trained at BIDMC as an intern and resident and began her research at BIDMC as well as joining the Hematology and Oncology Fellowship program and was recruited to join the medical staff as an attending physician in 2006. In addition to her clinical work and research Dr. Bhatt received her Masters of Medical Science during her participation in the Clinical Investigator Training Program in 2008.
http://www.bidmc.org/Centers-and-Departments/...-team.aspx
David Johnson Einstein, MD
Oncology Boston, MA
Genitourinary Oncology, Hematologic Oncology, Hospice & Palliative Fellow, BIDMC
Office Address
800 Washington St
Boston, MA 02111Phone
617) 667-2100
Title Clinical Fellow in Medicine (EXT)
Institution Beth Israel Deaconess Medical Center
Department Medicine
Address Beth Israel Deaconess Medical Center
Department of Medicine - Rabb 430
330 Brookline Ave
Boston MA 02215
Phone 617/667-9278
Fax 617/975-5009
Email
Education & Training
Tufts Medical CenterTufts Medical Center
Residency
Tufts University School of MedicineTufts University School of Medicine
Medical School
Other Training Certifications & Licensure
MA State Medical LicenseMA State Medical License 2011 - 2017
American Board of Internal Medicine
Internal Medicine
Awards, Honors, & Recognition
Merit Award in Palliative Care
Conquer Cancer Foundation of ASCO, 2014
Excellence in Teaching Award
Tufts University School of Medicine, 2014
Notable Teaching Citation
Tufts Medical Center Department of Medicine, 2013
Publications & Presentations
PubMed Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies.
Einstein, D. J.,DeSanto-Madeya, S.,Gregas, M.,Lynch, J.,McDermott, D. F.,Buss, M. K.; J Oncol Pract. 2017 Jun 01.
Against "Healthy Paternalism" at the End of Life-Reply.
Mathew P, Einstein DJ, Ladin K; JAMA Oncol. 2016-06-01.
The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life.
Einstein, D. J.,Ladin, K.,Mathew, P.; JAMA Oncol. 2016 Feb 26.
Journal Articles
The ethical imperative of healthy paternalism in advance-directive discussions at the end of life Einstein DJ, Ladin K, and Mathew P, JAMA Oncol, 1/25/2016
Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey Einstein DJ, Einstein KL, and Mathew P, J Palliat Med, 1/1/2015
A problematic palsy: an exercise in clinical reasoning Einstein DJ, Trowbridge RL, and Rencic J, J Gen Int Med, 1/1/2015
Abstracts/Posters
"Expanded Prostate Cancer Index Composite-26 Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life after Treatment for Lo... Einstein DJ, American Urological Association Annual Meeting, San Diego, CA, 1/1/2016
"Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey." Einstein DJ, ASCO Palliative Care in Oncology Symposium, Boston, MA, 1/1/2014
Lectures
"'Who Am I to Say?' The Role of Residents in Advance Care Planning." Boston, MA - 1/1/2016
Press Mentions
Peuxvn4ujpboexs1qudvDigital Journal
June 2017
OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas
BATON ROUGE, La., Feb. 05, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"
, a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is pleased to announce the signing of a Letter of Intent with Urology Clinics of North Texas (UCNT) for the purpose of initiating a Phase 2 Clinical Trial of ProscaVax in advanced prostate cancer patients. ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
Dr. James S. Cochran, M.D., D.A.B.U., F.A.C.S., UCNT Medical Director, has agreed to serve as the trial’s Principal Investigator. Dr. Cochran has over 30 years of clinical practice experience and has participated in and provided oversight in more than 300 clinical trials.
Dr. James S. Cochran, M.D., D.A.B.U., F.A.C.S
Diplomate, American Board of Urology
Fellow, American College of Surgeons
http://www.urologyclinics.com/our_doctors/cochran.html
Treatment:
Dr. Cochran is board-certified in urology and provides diagnosis and treatment of male and female urological conditions.
Medical School:
•University of Texas Southwestern Medical School
Dallas, Texas 1970
Residency:
•Urology, University of Texas Southwestern Medical School
Affiliated Hospitals include Parkland Memorial Hospital, Dallas; V. A. Hospital; Children's Medical Center; Baylor University Medical Center
*Includes one year of general surgery
Dallas, Texas 1971 - 1976
Other Education:
•Rice University, B.A. Biology
Houston, Texas 1966
Internship:
•Internal Medicine, Parkland Memorial Hospital,
Dallas, Texas - July 1970 through June 1971
Fellowship:
•The University of Texas Southwestern Medical School
Department of Cell Biology, Dallas, Texas
June 1973 to July 1974
Board Certification:
•American Board of Urology
Licensure:
•Texas, 1970
Honors and Awards:
•Castle Connolly Medical selected Dr. Cochran at Urology Clinics of North Texas among the top 10% of doctors in specialty and region in 2011.
• Elected to Alpha Omega Alpha, 1970
• American Urological Association Competition, First Prize for Clinical Research, 1975.
• American Urological Association South Central Section Essay Contest, Third Prize, 1975.
• American Cancer Society Fellowship Grant, 1973-1974
Professional Societies:
•American Urological Association
• South Central Section, American Urological Association
• Texas Urological Society
• Fellow American College of Surgeons
• American Medical Association
• Texas Medical Association
• Dallas County Medical Society
• American Fertility Society
• Endourology Society
• Society for Minimally Invasive Surgery
• American Lithotripsy Society (Executive Committee Member; Chairman Third Party Reimbursement)
Publications/Papers Published:
• Cochran, James S., Walsh, P.C., Porter, J.D., Nicholson, T.C., and Peter, P.C.: Clinical Evaluation of Human Chorionic Gonadotropin Levels in Men with Testicular Tumors. Surgical Forum, 25:542,1974.
• Cochran, James S.: The Immunobiology of Human Male Reproductive System. Urology, 4:10, 1974.
• Cochran, James S., Walsh, P.C., Porter, J.C., Nicholson, T.C., Madden, J.D., and Peters, P.C.: The Endocrinology of Human Chorionic Gonadotropin Secreting Testicular Tumors. Journal of Urology, 114:549, 1975.
• Cochran, James S.: The Seminoma Decoy. Journal of Urology, 116:465, 1976.
• Cochran, James S., Weber, C. H., Nicholson, T.C., and Peters, P.C.: The Prognostic Significance of Serum Human Chorionic Gonadotropin Levels in Men with Testicular Tumors. Journal of Urology.
• Testicular Tumor: The Dallas Experience. Dallas County Medical Society, 1978.
• Cochran, James S., Kadesky, M.C.: A Private Practice Experience with Radical Retropubic Prostatectomy for Adenocarcinoma of the Prostate. Urology, 11:237, 1981.
• Loch, T., Gettys, T., Cochran, J.S., Fulgham, P.F., and Bertermann, H.: Computer-Aided Image Analysis in Transrectal Ultrasound of the Prostate. World Journal of Urology, Vol. 8, 1990.
Publications/Papers Presented:
• The Immunologic Consequences of Vasectomy. Presented at the 31st Annual Meeting of the American Fertility Society. April 4, 1975.
• Testicular Carcinoma; Surgical Grand Rounds, Parkland Memorial Hospital. May 14, 1976.
• Continuous Flow Irrigation for Staghorn Calculi During ESWL, A Cost Effective Maneuver: 2nd Annual International Conference on ESWL. March 2, 1986. Indianapolis, Indiana.
• Computer Assisted Tissue Characterization Analysis (TCA) of Prostatic Ultrasound in the Diagnosis of Carcinoma of the Prostate: Initial Experience with a Computer Tissue Characterization System. Presented at the 1989 Annual Meeting of the American Urological Association, May 13, 1989. Presented at the Endourology Society meeting in Vienna, Austria, 1991.
• Computer Assisted Tissue Characterization Analysis (TCA) of Prostatic Ultrasound in the Diagnosis of Carcinoma of the Prostate: Follow-up Experience with a Computed Tissue Characterization System. Presented at the American Urological Association Annual Meeting in San Antonio, Texas, May 1990. Presented at the Endourology Society meeting Vienna, Austria, 1991.
• Laparoscopic Pelvic Lymph Node Dissection in Patients Undergoing Radical Retropubic Prostatectomy. Presented at the Endourology Society meeting in Vienna, Austria, 1991.
• Loch, T., Bertermann, H., Gettys, T., Cochran, J., Fulgham, P.: Image Analysis System (IAS): Objective Ultrasound Image Analysis Leads to Prostate Cancer Characterization. Poster presented to the American Urological Association Annual Meeting at New Orleans, Louisiana, 1990.
• Fulgham, Pat F., Feagins, Brian A., Cochran, James S., Kadesky, Melvin C., Denman, John L., and Harrison, Clanton B.: Cost Analysis of Laparoscopic Lymphadenectomy in a Private Practice Setting. Presented American Urologic Association National Meeting, San Antonio, 1993.
• Fulgham, Pat F., Cochran, James S., Denman, John L., Harrison, Clanton B., Clark, Angela R., Kurtz, Helen S., and Kadesky, Melvin C.: The Effect of Previous Vasectomy on Early Detection of Prostate Cancer in 2300 Patients. Submitted, American Urologic Association National Meeting, San Francisco, 1994.
• Fulgham, Pat F., Cochran, James S., Roehrborn, Claus G., Feagins, Brian A., Kadesky, Melvin C., Denman, John L., Harrison, III, Clanton B. Effect of the Application of Age Specific Reference Ranges for Prostate Specific Antigen (PSA) on Biopsy and Cancer Detection of Prostate Cancer. Presented at the AUA South Central Section Meeting, Vancouver, British Columbia, August 1994.
• Fulgham, Pat F., Feagins, Brian A., Roehrborn, Claus G., Cochran, James S., Kadesky, Melvin C., Denman, John L., Harrison, III, B. ROC Curve Analysis of the Performance of Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) in the Early Detection of Prostate Cancer. Presented at the AUA South Central Section Meeting, Vancouver, British Columbia, August 1994.
• Fulgham, Pat, F., Cochran, James S., Denman, John L., Feagins, Brian, A., Gross, Michael B., Kadesky, Keith, T., Kadesky, Melvin, C., Clark, Angela, Roehrborn, Clause G. (Presented by Dr. Fulgham) Disappointing Results with Transurethral Alprostadil in Men with Erectile Dysfunction (ED) inUrology. Presented at the AUA meeting. San Diego, June 1998.
Volunteer Positions:
• President American Cancer Society, Dallas, Texas (1982)
• Board of Directors American Cancer Society, Texas
• National Board of Directors STEP Foundation (1980-1984)
• Salesmanship Club of Dallas (1990-Present)
• Deacon, Highland Park Presbyterian Church (1987-1993)
• Elder, Highland Park Presbyterian Church (1993-Present)
Patent Granted:
•U.S. Patent #5,215,521. Entitled, "Laparoscopy Organ “Laparoscopy Retrieval Apparatus and Procedure."
Business Positions Held:
• General Partner and Medical Director, Southwest Lithotripter Partners. Dallas, Texas
• Medical Director, Texas ESWL LTD, Dallas
Founding Share Holder and Chief Medical Officer, Physician Data Corporation, Atlanta GA
• Founding Share Holder and Chief Technical Officer, Chief Medical Scientist, Tissue Scan Technologies, Inc. Denver, Colorado
• Board of Directors Applied Voice Recognition Inc.(E-Docs.Net) Houston, Texas
• Medical Advisory Board, Prime Medical Systems, Inc. Austin, Texas
• Member of Board of Directors and Chief Medical Consultant, Cybercare, Inc. Dallas, Texas
• Board of Directors, (THRI) Texas Health Research Institute Advisory Board, (PIMIT) Presbyterian Institute for Minimally Invasive Technology
• Medical Advisory Board, Gilda’s Club North Texas
• Member Board of Directors of Cambridge Holdings Inc.
• Founder of Doctors on Call (DOCS)
Press releases http://oncbiomune.com/news/
70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time
January 10th, 2018
http://oncbiomune.com/2018/01/10/70-of-advanc...ling-time/
One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
December 21st, 2017
100% Overall Survival Rate in 14 Evaluable Patients at One-Year Follow-Up
http://oncbiomune.com/2017/12/21/one-year-fol...cal-trial/
100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
December 5th, 2017
http://oncbiomune.com/2017/12/05/100-of-prost...ogression/
80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
November 13th, 2017
http://oncbiomune.com/2017/11/13/80-of-prosta...follow-up/
OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine
October 17th, 2017
http://oncbiomune.com/2017/10/17/oncbiomune-p...r-vaccine/
OncBioMune CMO Producing First Batch of Tretinoin for Acute Promyelocytic Leukemia
September 29th, 2017
BATON ROUGE, La., Sept. 29, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company" , a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...]
OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
September 14th, 2017
BATON ROUGE, LA, Sept. 14, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company" , a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...]
OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment
August 31st, 2017
BATON ROUGE, LA--(August 31, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP)("OncBioMune" or the "Company" , a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a [...]
OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference
August 29th, 2017
BATON ROUGE, LA--(August 29, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]
Final Patient Completes Treatment in OncBioMune Clinical Trial of ProscaVax for Prostate Cancer
August 24th, 2017
BATON ROUGE, LA--(August 24, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company" , a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]
ProscaVax – A Novel Prostate Cancer Vaccine
The Company has developed a therapeutic cancer vaccine for prostate cancer patients using similar techniques developed for breast cancer patients. It is tested and laboratory proven and could become the standard of care for prostate cancer treatment. The Company incorporates scientifically proven and clinically validated treatments for cancer. We utilize patented technology developed and or acquired by OncBioMune. The intellectual property consists of multiple technologies combined with laboratory and clinical procedures that provide new insight into the treatment of cancer. The Company’s proprietary technology provides the necessary tools for the successful treatment of patient’s with a therapeutic vaccine. It is marketable and would be very profitable upon FDA approval.
The Company has data from a phase 1/2 clinical trial of their therapeutic prostate cancer vaccine. Patients with prostate cancer confirmed by biopsy and with an elevated PSA received the vaccine. We enrolled 12 patients in this study. All patients received their initial course of six vaccinations containing prostate specific antigen and biological adjuvant. Serum PSA concentrations were determined before initiating vaccination and 3-4 weeks after the 6th vaccination. Two-thirds of the prostate cancer patients’ PSAs decreased after vaccination. During the trial the prostate cancer patients received no other concurrent therapy (surgery, hormone, radiation, radioactive seeds, chemotherapy), and have additionally received three further vaccinations alternated with low dose IL-2 for the 6 months following the initial vaccinations. The Company developed the protocol for the vaccination of prostate cancer patients using techniques developed for vaccination of breast cancer patients. We are currently in a Phase 1 clinical trial at UCSD Medical School under an IND from the FDA with funding from the US Navy Cancer Vaccine Program. If proven effective clinically, it could become the standard of care for prostate cancer.
Information on the current clinical trial of ProscaVax can be found on the clinictrials.gov at https://clinicaltrials.gov/ct2/show/NCT020586...amp;rank=1.
OncBiomune's ProscaVax phase 2 trial investigators Beth Israel Deaconess Medical Center of Harvard Medical School...
Glenn J. Bubley, MD, Director of Genitourinary Oncology
Dr. Glenn Bubley is a renowned expert in genitourinary (GU) medical oncology with a primary focus on prostate cancer. As director of the multidisciplinary genitourinary cancer program involving medical, surgical and radiation oncologists as well as pathologists and basic scientists, he heads numerous clinical/translational trials. He is Co-Principal Investigator for the prestigious Prostate SPORE (Specialized Programs of Research Excellence) at the Dana Farber/Harvard Cancer Center. The research is a pilot of the development of an anti-prostate cancer agent specifically targeted to prostate cancer cells. He oversees the Hershey Family Prostate Cancer Tissue Bank and Data base at BIDMC, which has more than 1,000 specimens from prostate cancer patients over the past 13 years and directs interventional research for GU oncology as well, overseeing approximately 13 open trials for patients with prostate or bladder cancer. Dr. Bubley has authored numerous scientific, research and translation papers and articles in his area of expertise, prostate cancer. He serves as at BIDMC and is Associate Professor of Medicine at Harvard Medical School.
Rupal Bhatt, MD, PhD, MMS
Dr. Rupal Bhatt is Assistant Professor of Medicine at Harvard Medical School, an attending physician in the GU Oncology Program and researcher Dr. Bhatt currently cares for patients with prostate, bladder and testis cancer and has participated in clinical trials in these fields. Dr. Bhatt focuses her research on Renal Cell Carcinoma and Prostate Cancer with a special interest in the Mechanisms of Resistance to Antiangiogenic Therapy. For this work, she was awarded Young Investigator Awards from AACR and ASCO and was also was awarded the ASCO Career Development Award. Currently Dr. Bhatt is in the second year of her five-year Mentored Clinical Scientist Development Award from the National Cancer Institute designed to train clinicians committed to a career in laboratory or field-based research or to translational research with a laboratory focus.
She completed her medical training and graduate training at Cornell University Medical College and The Rockefeller University, where she received her MD/PhD degrees. She trained at BIDMC as an intern and resident and began her research at BIDMC as well as joining the Hematology and Oncology Fellowship program and was recruited to join the medical staff as an attending physician in 2006. In addition to her clinical work and research Dr. Bhatt received her Masters of Medical Science during her participation in the Clinical Investigator Training Program in 2008.
http://www.bidmc.org/Centers-and-Departments/...-team.aspx
David Johnson Einstein, MD
Oncology Boston, MA
Genitourinary Oncology, Hematologic Oncology, Hospice & Palliative Fellow, BIDMC
Office Address
800 Washington St
Boston, MA 02111Phone
617) 667-2100 Title Clinical Fellow in Medicine (EXT)
Institution Beth Israel Deaconess Medical Center
Department Medicine
Address Beth Israel Deaconess Medical Center
Department of Medicine - Rabb 430
330 Brookline Ave
Boston MA 02215
Phone 617/667-9278
Fax 617/975-5009
Education & Training
Tufts Medical CenterTufts Medical Center
Residency
Tufts University School of MedicineTufts University School of Medicine
Medical School
Other Training Certifications & Licensure
MA State Medical LicenseMA State Medical License 2011 - 2017
American Board of Internal Medicine
Internal Medicine
Awards, Honors, & Recognition
Merit Award in Palliative Care
Conquer Cancer Foundation of ASCO, 2014
Excellence in Teaching Award
Tufts University School of Medicine, 2014
Notable Teaching Citation
Tufts Medical Center Department of Medicine, 2013
Publications & Presentations
PubMed Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies.
Einstein, D. J.,DeSanto-Madeya, S.,Gregas, M.,Lynch, J.,McDermott, D. F.,Buss, M. K.; J Oncol Pract. 2017 Jun 01.
Against "Healthy Paternalism" at the End of Life-Reply.
Mathew P, Einstein DJ, Ladin K; JAMA Oncol. 2016-06-01.
The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life.
Einstein, D. J.,Ladin, K.,Mathew, P.; JAMA Oncol. 2016 Feb 26.
Journal Articles
The ethical imperative of healthy paternalism in advance-directive discussions at the end of life Einstein DJ, Ladin K, and Mathew P, JAMA Oncol, 1/25/2016
Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey Einstein DJ, Einstein KL, and Mathew P, J Palliat Med, 1/1/2015
A problematic palsy: an exercise in clinical reasoning Einstein DJ, Trowbridge RL, and Rencic J, J Gen Int Med, 1/1/2015
Abstracts/Posters
"Expanded Prostate Cancer Index Composite-26 Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life after Treatment for Lo... Einstein DJ, American Urological Association Annual Meeting, San Diego, CA, 1/1/2016
"Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey." Einstein DJ, ASCO Palliative Care in Oncology Symposium, Boston, MA, 1/1/2014
Lectures
"'Who Am I to Say?' The Role of Residents in Advance Care Planning." Boston, MA - 1/1/2016
Press Mentions
Peuxvn4ujpboexs1qudvDigital Journal
June 2017
OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas
BATON ROUGE, La., Feb. 05, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"
, a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is pleased to announce the signing of a Letter of Intent with Urology Clinics of North Texas (UCNT) for the purpose of initiating a Phase 2 Clinical Trial of ProscaVax in advanced prostate cancer patients. ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Dr. James S. Cochran, M.D., D.A.B.U., F.A.C.S., UCNT Medical Director, has agreed to serve as the trial’s Principal Investigator. Dr. Cochran has over 30 years of clinical practice experience and has participated in and provided oversight in more than 300 clinical trials.
Dr. James S. Cochran, M.D., D.A.B.U., F.A.C.S
Diplomate, American Board of Urology
Fellow, American College of Surgeons
http://www.urologyclinics.com/our_doctors/cochran.html
Treatment:
Dr. Cochran is board-certified in urology and provides diagnosis and treatment of male and female urological conditions.
Medical School:
•University of Texas Southwestern Medical School
Dallas, Texas 1970
Residency:
•Urology, University of Texas Southwestern Medical School
Affiliated Hospitals include Parkland Memorial Hospital, Dallas; V. A. Hospital; Children's Medical Center; Baylor University Medical Center
*Includes one year of general surgery
Dallas, Texas 1971 - 1976
Other Education:
•Rice University, B.A. Biology
Houston, Texas 1966
Internship:
•Internal Medicine, Parkland Memorial Hospital,
Dallas, Texas - July 1970 through June 1971
Fellowship:
•The University of Texas Southwestern Medical School
Department of Cell Biology, Dallas, Texas
June 1973 to July 1974
Board Certification:
•American Board of Urology
Licensure:
•Texas, 1970
Honors and Awards:
•Castle Connolly Medical selected Dr. Cochran at Urology Clinics of North Texas among the top 10% of doctors in specialty and region in 2011.
• Elected to Alpha Omega Alpha, 1970
• American Urological Association Competition, First Prize for Clinical Research, 1975.
• American Urological Association South Central Section Essay Contest, Third Prize, 1975.
• American Cancer Society Fellowship Grant, 1973-1974
Professional Societies:
•American Urological Association
• South Central Section, American Urological Association
• Texas Urological Society
• Fellow American College of Surgeons
• American Medical Association
• Texas Medical Association
• Dallas County Medical Society
• American Fertility Society
• Endourology Society
• Society for Minimally Invasive Surgery
• American Lithotripsy Society (Executive Committee Member; Chairman Third Party Reimbursement)
Publications/Papers Published:
• Cochran, James S., Walsh, P.C., Porter, J.D., Nicholson, T.C., and Peter, P.C.: Clinical Evaluation of Human Chorionic Gonadotropin Levels in Men with Testicular Tumors. Surgical Forum, 25:542,1974.
• Cochran, James S.: The Immunobiology of Human Male Reproductive System. Urology, 4:10, 1974.
• Cochran, James S., Walsh, P.C., Porter, J.C., Nicholson, T.C., Madden, J.D., and Peters, P.C.: The Endocrinology of Human Chorionic Gonadotropin Secreting Testicular Tumors. Journal of Urology, 114:549, 1975.
• Cochran, James S.: The Seminoma Decoy. Journal of Urology, 116:465, 1976.
• Cochran, James S., Weber, C. H., Nicholson, T.C., and Peters, P.C.: The Prognostic Significance of Serum Human Chorionic Gonadotropin Levels in Men with Testicular Tumors. Journal of Urology.
• Testicular Tumor: The Dallas Experience. Dallas County Medical Society, 1978.
• Cochran, James S., Kadesky, M.C.: A Private Practice Experience with Radical Retropubic Prostatectomy for Adenocarcinoma of the Prostate. Urology, 11:237, 1981.
• Loch, T., Gettys, T., Cochran, J.S., Fulgham, P.F., and Bertermann, H.: Computer-Aided Image Analysis in Transrectal Ultrasound of the Prostate. World Journal of Urology, Vol. 8, 1990.
Publications/Papers Presented:
• The Immunologic Consequences of Vasectomy. Presented at the 31st Annual Meeting of the American Fertility Society. April 4, 1975.
• Testicular Carcinoma; Surgical Grand Rounds, Parkland Memorial Hospital. May 14, 1976.
• Continuous Flow Irrigation for Staghorn Calculi During ESWL, A Cost Effective Maneuver: 2nd Annual International Conference on ESWL. March 2, 1986. Indianapolis, Indiana.
• Computer Assisted Tissue Characterization Analysis (TCA) of Prostatic Ultrasound in the Diagnosis of Carcinoma of the Prostate: Initial Experience with a Computer Tissue Characterization System. Presented at the 1989 Annual Meeting of the American Urological Association, May 13, 1989. Presented at the Endourology Society meeting in Vienna, Austria, 1991.
• Computer Assisted Tissue Characterization Analysis (TCA) of Prostatic Ultrasound in the Diagnosis of Carcinoma of the Prostate: Follow-up Experience with a Computed Tissue Characterization System. Presented at the American Urological Association Annual Meeting in San Antonio, Texas, May 1990. Presented at the Endourology Society meeting Vienna, Austria, 1991.
• Laparoscopic Pelvic Lymph Node Dissection in Patients Undergoing Radical Retropubic Prostatectomy. Presented at the Endourology Society meeting in Vienna, Austria, 1991.
• Loch, T., Bertermann, H., Gettys, T., Cochran, J., Fulgham, P.: Image Analysis System (IAS): Objective Ultrasound Image Analysis Leads to Prostate Cancer Characterization. Poster presented to the American Urological Association Annual Meeting at New Orleans, Louisiana, 1990.
• Fulgham, Pat F., Feagins, Brian A., Cochran, James S., Kadesky, Melvin C., Denman, John L., and Harrison, Clanton B.: Cost Analysis of Laparoscopic Lymphadenectomy in a Private Practice Setting. Presented American Urologic Association National Meeting, San Antonio, 1993.
• Fulgham, Pat F., Cochran, James S., Denman, John L., Harrison, Clanton B., Clark, Angela R., Kurtz, Helen S., and Kadesky, Melvin C.: The Effect of Previous Vasectomy on Early Detection of Prostate Cancer in 2300 Patients. Submitted, American Urologic Association National Meeting, San Francisco, 1994.
• Fulgham, Pat F., Cochran, James S., Roehrborn, Claus G., Feagins, Brian A., Kadesky, Melvin C., Denman, John L., Harrison, III, Clanton B. Effect of the Application of Age Specific Reference Ranges for Prostate Specific Antigen (PSA) on Biopsy and Cancer Detection of Prostate Cancer. Presented at the AUA South Central Section Meeting, Vancouver, British Columbia, August 1994.
• Fulgham, Pat F., Feagins, Brian A., Roehrborn, Claus G., Cochran, James S., Kadesky, Melvin C., Denman, John L., Harrison, III, B. ROC Curve Analysis of the Performance of Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) in the Early Detection of Prostate Cancer. Presented at the AUA South Central Section Meeting, Vancouver, British Columbia, August 1994.
• Fulgham, Pat, F., Cochran, James S., Denman, John L., Feagins, Brian, A., Gross, Michael B., Kadesky, Keith, T., Kadesky, Melvin, C., Clark, Angela, Roehrborn, Clause G. (Presented by Dr. Fulgham) Disappointing Results with Transurethral Alprostadil in Men with Erectile Dysfunction (ED) inUrology. Presented at the AUA meeting. San Diego, June 1998.
Volunteer Positions:
• President American Cancer Society, Dallas, Texas (1982)
• Board of Directors American Cancer Society, Texas
• National Board of Directors STEP Foundation (1980-1984)
• Salesmanship Club of Dallas (1990-Present)
• Deacon, Highland Park Presbyterian Church (1987-1993)
• Elder, Highland Park Presbyterian Church (1993-Present)
Patent Granted:
•U.S. Patent #5,215,521. Entitled, "Laparoscopy Organ “Laparoscopy Retrieval Apparatus and Procedure."
Business Positions Held:
• General Partner and Medical Director, Southwest Lithotripter Partners. Dallas, Texas
• Medical Director, Texas ESWL LTD, Dallas
Founding Share Holder and Chief Medical Officer, Physician Data Corporation, Atlanta GA
• Founding Share Holder and Chief Technical Officer, Chief Medical Scientist, Tissue Scan Technologies, Inc. Denver, Colorado
• Board of Directors Applied Voice Recognition Inc.(E-Docs.Net) Houston, Texas
• Medical Advisory Board, Prime Medical Systems, Inc. Austin, Texas
• Member of Board of Directors and Chief Medical Consultant, Cybercare, Inc. Dallas, Texas
• Board of Directors, (THRI) Texas Health Research Institute Advisory Board, (PIMIT) Presbyterian Institute for Minimally Invasive Technology
• Medical Advisory Board, Gilda’s Club North Texas
• Member Board of Directors of Cambridge Holdings Inc.
• Founder of Doctors on Call (DOCS)
Press releases http://oncbiomune.com/news/
70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time
January 10th, 2018
http://oncbiomune.com/2018/01/10/70-of-advanc...ling-time/
One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
December 21st, 2017
100% Overall Survival Rate in 14 Evaluable Patients at One-Year Follow-Up
http://oncbiomune.com/2017/12/21/one-year-fol...cal-trial/
100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
December 5th, 2017
http://oncbiomune.com/2017/12/05/100-of-prost...ogression/
80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
November 13th, 2017
http://oncbiomune.com/2017/11/13/80-of-prosta...follow-up/
OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine
October 17th, 2017
http://oncbiomune.com/2017/10/17/oncbiomune-p...r-vaccine/
OncBioMune CMO Producing First Batch of Tretinoin for Acute Promyelocytic Leukemia
September 29th, 2017
BATON ROUGE, La., Sept. 29, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"
, a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...] OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
September 14th, 2017
BATON ROUGE, LA, Sept. 14, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"
, a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer [...] OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment
August 31st, 2017
BATON ROUGE, LA--(August 31, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP)("OncBioMune" or the "Company"
, a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a [...] OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference
August 29th, 2017
BATON ROUGE, LA--(August 29, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...] Final Patient Completes Treatment in OncBioMune Clinical Trial of ProscaVax for Prostate Cancer
August 24th, 2017
BATON ROUGE, LA--(August 24, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"
, a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...] 
